Expedited Pathways Comparisons - US EU CHN

This presentation from Parexel's virtual roundtable, entitled "Making expedited regulatory pathways work for global drug development programs" outlines regional comparisons of expedited pathways in US, EU and China.


Open PDF

Return to Insights Center

Related Insights

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Video

Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Blog

Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Article

How emerging biotechs can enter the Chinese market and prosper

Jan 18, 2022

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024